16 Stocks Moving In Monday's Pre-Market Session

Gainers

• Clearside Biomedical Inc CLSD rose 40.8 percent to $32.91 in pre-market trading after rising 15.98 percent on Friday. Clearside Biomedical disclosed that it will report results from two clinical trials at the 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology Meeting.
• IntelliPharmaCeutics Intl Inc (USA) IPCI rose 34.5 percent to $3.20 in pre-market trading as the company reported the FDA tentative approval for generic Seroquel XR on Friday.
• TESARO Inc TSRO rose 14.9 percent to $114.00 in pre-market trading. TESARO and ENGOT reported the presentation of successful niraparib Phase 3 ENGOT-OV16/NOVA trial results during the ESMO 2016.
• Mylan NV MYL rose 13 percent to $40.60 in pre-market trading after the company reported a deal to settle on EpiPen classification rebates to Medicaid. As per a press release, the company agreed to a $465 million settlement with U.S. several government agencies, including the Department of Justice, but did not recognize any wrongdoing.
• Enzo Biochem, Inc. ENZ rose 10.7 percent to $5.68 in pre-market trading. Enzo Biochem is expected to report fiscal 2016 fourth quarter results on October 14, 2016.
• Ceragon Networks Ltd CRNT rose 8.3 percent to $2.47 in pre-market trading. Ceragon Networks is expected to report Q3 results on November 14, 2016.
• Mazor Robotics Ltd - ADR MZOR rose 7 percent to $23.80 in pre-market trading after the company announced first pre-launch orders for Mazor X system.
• Aurinia Pharmaceuticals Inc AUPH shares rose 5.3 percent to $4.95 in pre-market trading after dropping 7.84 percent on Friday.
• Exelixis, Inc. EXEL rose 5 percent to $13.60 in the pre-market trading after the company announced positive results from the Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma.
• Celldex Therapeutics, Inc. CLDX rose 4.6 percent to $4.33 in the pre-market trading session as the company presented positive results from the Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory at the ESMO 2016.
• Egalet Corp EGLT shares rose 4.2 percent to $7.74 in pre-market trading after climbing 7.53 percent on Friday.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

• Twitter Inc TWTR shares fell 12.6 percent to $17.34 in pre-market trading following a Bloomberg report which suggested the social media company is no longer being targeted for an acquisition. According to Bloomberg, potential bidders reportedly lost interest in acquiring Twitter due to pressure from their major investors. Companies such as salesforce.com, inc. CRM, Walt Disney Co DIS and Alphabet Inc GOOG GOOGL's Google unit all consulted with their respective financial advisers and bankers and the conclusion that was reached appears to be unfavorable for Twitter investors who were hoping a takeout would occur at a hefty premium.
• Dover Corp DOV shares fell around 7.7 percent in pre-market trading after the company cut its earnings and sales guidance for the year.
• Myriad Genetics, Inc. MYGN shares fell 7.5 percent to $19.75 in pre-market trading after the company disclosed that its myChoice HRD test identified patients with ovarian cancer who may benefit from treatment with niraparib.
• Bristol-Myers Squibb Co BMY shares fell 6.6 percent to $51.80 in pre-market trading as the company presented results from Phase 1 CheckMate -016 trial at the ESMO 2016.
• Twilio Inc TWLO shares fell 6.2 percent to $56.85 in pre-market trading.